Department Metrics
View the grants, clinical trials and publications from the Metabolism and Physiology Department.
-
Grants
- Impact of extracellular glutathione catabolism on triple-negative breast cancer
Award Number:
Sponsor: Nat Institutes of Health
PI:DeNicola, G. - Ecology and Evolution of Breast Carcinogenesis
Award Number:
Sponsor: Nat Institutes of Health
PI:Silva, A. - Translational studies for targeted alpha-particle therapy for rare melanomas
Award Number:
Sponsor: US Army
PI:Morse, D. - Improving therapy for leptomeningeal Non-Hodgkin B cell lymphoma by targeting the metabolic tumor microenvironment
Award Number:
Sponsor: Amer Cancer Society
PI:Smalley, I.
- Impact of extracellular glutathione catabolism on triple-negative breast cancer
-
Publications
- Bryant JM, Shotbolt M, Stimphil E, Andre V, Zhang E, Estrella V, Husain K, Weygand J, Marchion D, Lopez AS, Abrahams D, Chen S, Abdel-Mottaleb M, Conlan S, Oraiqat I, Khatri V, Guevara JA, Pilon-Thomas S, Redler G, Latifi K, Raghunand N, Yamoah K, Hoffe S, Costello J, Frakes JM, Liang P, Gatenby RA, Malafa M, Khizroev S. Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models. Adv Sci (Weinh). 2026 Feb.13(9):e17228. Pubmedid: 41178530. Pmcid: PMC12904064.
- Hammami MB, Canevarolo RR, Silva AS, Alsina M, Kumar N, Baz R, Shain KH. Navigating the evolving management of smoldering multiple myeloma. Hemasphere. 2026 Jan.10(1):e70275. Pubmedid: 41523082. Pmcid: PMC12784114.
- Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2026 Jan.147(5):497-512. Pubmedid: 40983035.
- Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, Garces JJ, Firestone R, Braggio E, Asmann Y, Durante M, Diamond BT, Papadimitriou M, Hultcrantz M, Marella A, Castellano G, Maeda A, Lionetti M, Matera A, Pioggia S, Da Vià MC, de Magistris C, Leongamornlert D, DeAvila D, Sudalagunta PR, Canevarolo RR, Siegel EM, Agius P, Teer J, McPherson A, Yamashita Y, Silva AS, Blaney P, Baz R, Patel KK, Campbell P, Morgan G, Fonseca R, Landgren O, Orlowski RZ, Shain KH, Bolli N, Usmani S, Rajkumar SV. Genomics Define Malignant Transformation in Myeloma Precursor Conditions. J Clin Oncol. 2026 Jan.44(3):188-199. Pubmedid: 41061199. Pmcid: PMC12614327.
- Maura F, Freeman CL, Maclachlan KH, Ilundain ML, Ziccheddu B, Meermeier EW, Garces JJ, Durante M, Lee H, Firestone R, Menges M, Reid K, Diamond B, Papadimitriou M, Silva AS, Sudalagunta PR, Leblay N, Ahn S, Fuller E, Briercheck E, Sharik ME, Du MT, Agius P, Hansen DK, Song X, Zhao X, Meads MB, Teer J, Jelinek T, Hagner P, Baz R, Alsina M, Ramasubramanian AM, Smith E, Giralt SA, Mailankody S, Bergsagel LP, Neri P, Chesi M, Martinez-Climent JA, Locke FL, Bahlis NJ, Landgren O, Hamadeh I, Usmani SZ, Shain KH. Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma. bioRxiv. 2025 Dec. Pubmedid: 41415462. Pmcid: PMC12710967.
- Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Dec.43(12):2298-2310.e6. Pubmedid: 41072416. Pmcid: PMC12614569.
- Kim Y, Caldwell S, Long M, Abrahams D, Baldwin M, DeNicola GM. A simple, anesthesia-free infusion technique for in vivo metabolic tracing. bioRxiv. 2025 Dec. Pubmedid: 41473331. Pmcid: PMC12746135.
- Yasseen BA, DeNicola GM. Can't KEEP Up: UXS1 Dependency Exposes a Pyrimidine Vulnerability in KEAP1-Mutant Lung Cancer. Cancer Res. 2025 Dec.85(23):4582-4584. Pubmedid: 41321105.
- Tiek D, Song X, Wu R, Yu X, Walker M, Mao Y, Sisbarro D, He Q, Magassa A, Singh A, Lu J, Sharma AK, Miska J, Hu B, Bonini MG, Zhang X, Cheng SY. Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds. Neurooncol. 2025 Nov. Pubmedid: 41212520.
- Weinfurtner RJ, Ataya D, Funaro K, Bhatt A, Abdalah M, Stringfield O, Raghunand N, Thompson Z, Lee MC, Czerniecki B, Muller AS, Soliman H, Han H. Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy. Clin Imaging. 2025 Nov.127:110618. Pubmedid: 40945432.
- Tauro M, Li T, Sudalagunta PR, Meads M, Canevarolo RR, Nerlakanti N, Alugubelli RR, Lawrence HR, Gunawan S, Ayaz M, Nareddy P, Yun SY, Shay G, Yang K, Tran TH, Bishop RT, Nasr MM, Lawrence NNJ, Schönbrunn E, Cleveland JL, Silva AS, Shain KH, Lynch CC. Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma. Res Sq. 2025 Aug. Pubmedid: 40831505. Pmcid: PMC12363935.
- Piña Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, Mokhtari S, Evernden B, Ahmed KA, Smalley I, Yu M, Smalley KSM, Forsyth PA. Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses. Neurooncol. 2025 Aug. Pubmedid: 40888040.
- Persi E, Sudalagunta PR, Wolf YI, Canevarolo RR, Damaghi M, Shain KH, Silva AS, Koonin EV. Genome-level selection in tumors as a universal marker of resistance to therapy. Nat Commun. 2025 Jul.16(1):6535. Pubmedid: 40664650. Pmcid: PMC12263839.
- Andreani C, Bartolacci C, Melegari M, Sargentoni N, Luciani L, Marucci A, Galeazzi R, DeNicola GM, Kilgore J, Williams N, Berto S, Gaetani M, Pattabhi P, Osman SS, Mansour AT, Pucciarelli S, Galassi R, Scaglioni PP. Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers. bioRxiv. 2025 Jul. Pubmedid: 40766571. Pmcid: PMC12324224.
- Bishop RT, Li T, Sudalagunta P, Nasr M, Nyman KJ, Alugubelli RR, Meads M, Frieling J, Nerlakanti N, Tauro M, Fang B, Grant S, Koomen J, Silva AS, Shain KH, Lynch CC. Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma. Haematologica. 2025 Jun.110(6):1351-1367. Pubmedid: 39633543. Pmcid: PMC12130774.
- Sherwood AM, Yasseen BA, DeBlasi JM, Caldwell S, DeNicola GM. Distinct roles for the thioredoxin and glutathione antioxidant systems in Nrf2-Mediated lung tumor initiation and progression. Redox Biol. 2025 Jun.83:103653. Pubmedid: 40334547. Pmcid: PMC12133717.
- Renatino Canevarolo R, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst LA, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer JB, Dalton WS, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Res Sq. 2025 Apr. Pubmedid: 40321765. Pmcid: PMC12048002.
- Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
- Cuadrado A, Cazalla E, Bach A, Bathish B, Naidu SD, DeNicola GM, Dinkova-Kostova AT, Fernández-Ginés R, Grochot-Przeczek A, Hayes JD, Kensler TW, León R, Liby KT, López MG, Manda G, Shivakumar AK, Hakomäki H, Moerland JA, Motohashi H, Rojo AI, Sykiotis GP, Taguchi K, Valverde ÁM, Yamamoto M, Levonen AL. Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases. Redox Biol. 2025 Apr.81:103569. Pubmedid: 40059038. Pmcid: PMC11970334.
- Ospina OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, Smalley I, Tsai KY, Markowitz J, Vallebuona E, Berglund AE, Eschrich SA, Yu X, Fridley BL. spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data Analysis. Cancer Res. 2025 Mar.85(5):848-858. Pubmedid: 39636739. Pmcid: PMC11873723.
- Roy J, Putt KS, Coppola D, Leon ME, Khalil FK, Centeno BA, Clark N, Stark VE, Morse DL, Low PS. Addendum: Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue. Oncotarget. 2025 Mar.16:132. Pubmedid: 40042992. Pmcid: PMC11884436.